Aybintio (bevacizumab biosimilar) / Samsung, 3SBio, Mundipharma - LARVOL DELTA

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (clinicaltrials.gov) - P3 | N=408 | Recruiting | Sponsor: ECOG-ACRIN Cancer Research Group | Trial completion date: Jun 2034 ➔ Jun 2029

Trial completion date • Colorectal Cancer • Oncology • Solid Tumor

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy (clinicaltrials.gov) - P2 | N=87 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | Initiation date: Sep 2026 ➔ Jun 2027

Enrollment open • Platinum sensitive • Trial initiation date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD

ON-Going Care in mCRC: Strategies for Long-Term Disease Control with Bevacizumab Combination Therapy (IASGO 2026) - "In refractory mCRC, the SUNLIGHT trial showed that trifluridinetipiracil plus bevacizumab improved overall and progression-free survival compared with trifluridinetipiracil alone. Regorafenib and fruquintinib remain additional later-line options for appropriate patients.Tolerability, marrow reserve, organ function, performance status, and patient preference should guidesequencing. A case with prolonged disease control across bevacizumab-FOLFIRI, surgery, bevacizumab-FOLFOX,radiotherapy, and later-line therapy demonstrates the value of coordinated sequential decisions.Korean post-marketing experience with the SB8 bevacizumab biosimilar (ONBEVZI) providessupportive real-world information and may help expand access. The goal is not simply to maximize oneregimen's duration, but to preserve function and deliver active therapy across the entire disease course."

Combination therapy • Colorectal Cancer • Solid Tumor • BRAF

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Organ System-Specific Trends in Congenital Anomaly Admissions following Texas Senate Bill 8. (PubMed, J Pediatr Surg) - "Newborn congenital anomaly admissions increased in the period following SB8, coinciding with a reversal of declining operative volumes. Operative intensity and temporal trends varied substantially by organ system. Mortality remained low overall but increased notably in circulatory and respiratory categories. These findings underscore the importance of organ system-specific evaluation of outcomes following reproductive policy changes."

Journal

Peptide ligands targeting GP64 for the purification of Baculovirus from insect cell lysates. (PubMed, J Chromatogr A) - "Eight candidate peptides (SB1-SB8) were evaluated on Toyopearl and POROS chromatographic resins, demonstrating that matrix chemistry, pore size, and ligand density govern purification performance. The SB4-POROS resin demonstrated storage stability and ∼80% retention of binding capacity over ten purification-regeneration cycles with caustic cleaning. Integration into a three-step downstream process (clarification, affinity capture, and polishing) raised product purity 1,528-fold, from 6.22 × 106 to 9.50 × 109 viral genomes per µg of HCP, while reducing the total HCP burden 1,698-fold, at a cumulative transducing-unit yield of ∼69% relative to the feedstock, establishing SB4-POROS as a promising technology with a favorable projected cost structure for Baculovirus purification."

Journal

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial (clinicaltrials.gov) - P3 | N=226 | Recruiting | Sponsor: NRG Oncology | Trial completion date: Mar 2029 ➔ Mar 2034

Trial completion date • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • IL2

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial (clinicaltrials.gov) - P3 | N=129 | Not yet recruiting | Sponsor: City of Hope Medical Center | Initiation date: Jul 2026 ➔ Oct 2026

Trial initiation date • Appendix Cancer • Colorectal Cancer • Oncology • Solid Tumor • BRAF

A092001: Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2026 ➔ Aug 2027 | Trial primary completion date: Aug 2026 ➔ Aug 2027

Trial completion date • Trial primary completion date • Mesothelioma • Oncology • Peritoneal Mesothelioma • Psoriatic Arthritis • Solid Tumor

A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial (clinicaltrials.gov) - P=N/A | N=202 | Recruiting | Sponsor: Mayo Clinic | N=120 ➔ 202

Enrollment change • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov) - P2 | N=4 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | N=88 ➔ 4 | Trial completion date: Sep 2026 ➔ Aug 2027 | Trial primary completion date: Sep 2026 ➔ Jan 2026

Enrollment change • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Psoriatic Arthritis • Solid Tumor • IL2

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (clinicaltrials.gov) - P2 | N=5 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - P1/2 | N=85 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Aug 2029 ➔ Feb 2031 | Trial primary completion date: Aug 2029 ➔ May 2030

Checkpoint inhibition • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov) - P2 | N=88 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2026 ➔ Sep 2026 | Trial primary completion date: Jun 2026 ➔ Sep 2026

Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Psoriatic Arthritis • Solid Tumor • IL2

The Texas Abortion Ban and Maternal Mental Health. (PubMed, JAMA Netw Open) - "To examine the association of the implementation of Texas Senate Bill 8 (SB8) abortion law, which banned abortions after embryonic cardiac activity in September 2021, with maternal mental health outcomes...In this repeated cross-sectional study, the implementation of an abortion ban in Texas was associated with a worsening of maternal mental health among reproductive-age mothers relative to mothers in states without such bans. These results underscore the association of abortion restrictions with maternal mental health and highlight the need to strengthen support in the post-Dobbs policy environment."

Journal • CNS Disorders • Psychiatry • Women's Health

Critical Illness Outcomes of Hospitalized Pregnant Women Following a Texas Abortion Ban. (PubMed, Am J Respir Crit Care Med) - "Following SB8, hospitalized pregnant women with high-risk features experienced significant increases in rates of critical illness, sepsis, and infection. These results may inform infection prevention programs and critical illness training in abortion-restrictive states."

Journal • Infectious Disease • Septic Shock

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (clinicaltrials.gov) - P1/2 | N=460 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | N=280 ➔ 460

Enrollment change • Platinum resistant • Platinum sensitive • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor

ECOG-ACRIN 5103: Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (clinicaltrials.gov) - P3 | N=4994 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2026 ➔ Feb 2027

Trial completion date • Breast Cancer • Oncology • Solid Tumor • ER • HER-2

NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P2/3 | N=444 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2026 ➔ Apr 2027

Platinum resistant • Trial completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • PD-L1

Toward a Crisis Pregnancy Center Client Typology: Abortion-Seekers' Expectations and Experiences Following Implementation of Texas' Early Abortion Ban. (PubMed, Perspect Sex Reprod Health) - "In addition to contacting CPCs because they were deceived or pragmatic, pregnant Texans considering abortion after SB8 drew on CPC services strategically. In an abortion-restrictive setting, pregnant people may try to use CPCs for free services that they cannot get as easily from licensed medical providers."

Journal

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov) - P2 | N=349 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2026 ➔ Mar 2027

Trial completion date • Carcinosarcoma • Endometrial Adenocarcinoma • Endometrial Cancer • Endometrial Serous Adenocarcinoma • Oncology • Sarcoma • Solid Tumor • Uterine Cancer • AKT1

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P3 | N=403 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2026 ➔ Feb 2027

Trial completion date • Head and Neck Cancer • Hypopharyngeal Cancer • Lung Cancer • Oncology • Oral Cancer • Oropharyngeal Cancer • Salivary Gland Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Carcinoma of Unknown Primary • Tongue Carcinoma

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (clinicaltrials.gov) - P3 | N=50 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2026 ➔ Mar 2027

Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor

S0533: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2 | N=29 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Feb 2026 ➔ Feb 2027

Trial completion date • Large Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma (clinicaltrials.gov) - P2 | N=92 | Not yet recruiting | Sponsor: Yonsei University

New P2 trial • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor